Topical CBD and transdermal CBD are designed for different kinds of delivery. A standard topical is intended for the skin and the area where it is placed; a product labeled transdermal is intended to move an ingredient through the skin and into circulation. That difference matters when you are deciding what a cream, gel, or patch is actually offering—and when you are judging a claim based on an oral CBD study.
CBD itself is not intoxicating like THC, according to the FDA’s cannabis guidance. But a label that says “CBD topical” does not, by itself, tell you whether a product is local-only or designed for transdermal delivery. Start with the delivery claim, the cannabinoid list, and the batch-specific lab report.
What is the difference in intended delivery?
Think of the skin as a gate. A topical product is meant to sit on or work within the skin and nearby tissue. A transdermal product is formulated with the goal of getting an ingredient across that gate and into the bloodstream.
| Product description | Intended delivery | What that means for your questions |
|---|---|---|
| Topical cream, balm, lotion, or gel | Local skin-area delivery | Look for the complete ingredient list and any claim about the specific area of skin or body. |
| Transdermal patch, cream, or gel | Through the skin toward systemic delivery | Ask whether the label specifically says transdermal, what ingredients support that design, and whether the lab report matches the package. |
| Oral CBD product | Swallowed and processed through the body | Its research belongs to an oral route; it is not a stand-in for a topical or transdermal product. |
Ethos Cannabis describes transdermal products as products intended to enter the bloodstream, while describing most cannabis topicals as localized. That is a useful description of intended delivery, but it is still important to read the specific package and its lab report. Our guide to topical and bloodstream delivery walks through the terms in more detail.
Can CBD be absorbed through the skin?
Yes, a product may be designed to move CBD through the skin, but “applied to skin” and “transdermal” are not interchangeable words. A product’s formula, its delivery claim, and the amount it is designed to deliver all matter. The 2022 topical-CBD review indexed by PubMed describes scientific interest in CBD used on skin and discusses cannabinoid receptors in skin; it does not establish that every CBD cream reaches the bloodstream or produces the same outcome.
For a cream, balm, or roll-on, do not assume that a large number on the front label proves transdermal delivery. “1,500 mg” may describe CBD in the entire container, not what reaches the skin or circulation. The practical question is: does the maker call it transdermal, explain the delivery system, and provide a batch-linked certificate of analysis?
Do transdermal CBD patches work?
A transdermal patch is intended to release CBD through the skin over time. Whether a particular patch delivers what its package promises is a product-specific question. Its label and certificate of analysis should identify the CBD amount, the cannabinoid profile, the batch or lot number, and the laboratory that issued the report.
Human outcome research cannot be borrowed from a different route. The 2022 randomized trial indexed by PubMed tested topical CBD after total knee arthroplasty in 80 participants. It found no reduction in pain, opioid consumption, or sleep-score improvement compared with the study’s comparison groups. That result concerns that topical preparation, people recovering from knee replacement, and those measured outcomes; it does not answer whether a different transdermal patch delivers CBD into circulation or how another formulation performs.
Can an oral CBD study support a topical claim?
No—not on its own. Oral CBD and a skin-applied CBD product have different intended routes. An oral study can tell you about the oral product, population, and outcome that researchers measured. It cannot establish that a topical cream or transdermal patch has the same delivery, exposure, or result.
This is especially important when a product page uses research language. Keep the claim connected to the route: oral findings belong with oral products; topical findings belong with topical formulations; transdermal findings need transdermal evidence. For a simple way to separate a product statement from the study behind it, see claim questions.
Why do people ask about CBD cream for joints and muscles?
People often search for CBD cream for muscle discomfort, joint discomfort, or arthritis because a topical format is marketed around a particular body area. The 2022 skin-focused review discusses possible anti-inflammatory, anti-itching, analgesic, wound-healing, and anti-proliferative effects in the context of topical cannabis research. Those are research topics, not a promise that a cream will address arthritis or another condition.
The knee-replacement trial gives one concrete example of why route- and setting-specific evidence matters: its topical CBD preparation did not improve the postoperative outcomes it measured. For arthritis questions, a clinician can help you put any product claim alongside your diagnosis, current care, and medications.
Is CBG or CBD better for arthritis pain?
The studies here do not compare CBG with CBD for arthritis pain, so this page cannot rank one over the other. A useful next question for a clinician is whether the product’s route, full ingredient list, and your existing care make sense together. Avoid treating a cannabinoid label as a substitute for a plan for an ongoing joint condition.
Would CBD cream make you high?
CBD is not intoxicating like THC, according to the FDA. THC is the cannabinoid associated with intoxicating effects. Still, product labels and lab reports matter because the FDA says consumer CBD products may contain a different amount of CBD than the label states and may contain contaminants, including THC.
If avoiding THC matters to you—for work, driving, or personal reasons—read the cannabinoid panel and the batch-specific lab report before buying. Our THC label guide explains the label math and legal-limit language without assuming that every package says the same thing.
What about liver, kidneys, and medication interactions?
The FDA says CBD has been associated with liver injury and can interact with other medicines; the agency’s discussion is based in part on information from studies of the FDA-approved oral CBD drug Epidiolex and other published literature. The FDA also says there are unanswered questions about how different routes, including topical use, affect intake. That means a route label does not settle a medication-interaction question.
For kidney disease, liver concerns, or prescription medicines, bring the product label and its cannabinoid amounts to the clinician who manages your care before making a decision. Do not start, stop, or change a medication based on a general CBD article.
What does the law say about hemp and CBD?
As of the FDA page captured October 5, 2026, the FDA says the Agriculture Improvement Act of 2018 (the 2018 Farm Bill, Public Law 115-334), signed December 20, 2018, removed hemp meeting the statutory THC definition from the Controlled Substances Act’s definition of marijuana. The FDA also says hemp status does not remove other applicable FDA requirements for CBD products. This is information, not legal advice.
The legal status of a product can also depend on its intended use, labeling, and state rules. The FDA says it has approved Epidiolex, a prescription CBD drug for specified seizure disorders, and no other CBD-containing drug products. A cream or patch sold online is not the same thing as that prescription product.
Plain-language glossary
| Term | Plain meaning |
|---|---|
| CBD | Cannabidiol, a cannabis compound that the FDA says is not intoxicating like THC. |
| THC | A cannabis compound associated with intoxicating effects. |
| Topical | A product intended for use on the skin or a particular body area. |
| Transdermal | A product formulated with the intended goal of moving an ingredient through the skin and into circulation. |
| Systemic | Reaching circulation and potentially affecting more than the place where a product is applied. |
| COA | Certificate of analysis: a laboratory report tied to a product batch or lot. |
| Batch or lot number | The identifier that lets you match a package to its lab report. |
Before you order: five quick checks
- Decide whether the package says topical or transdermal; do not treat the words as synonyms.
- Match the batch or lot number on the package to the certificate of analysis.
- Read the full cannabinoid and non-cannabinoid ingredient list, especially if you have skin sensitivities.
- Ask the seller for the current label and batch report if either is missing.
- Bring route-specific questions, medication questions, and ongoing pain concerns to your clinician.
The clearest next step is to read the route-specific label language, keep the COA with the package information, and prepare the questions you want answered in care.
By TakeHempGummies.com Consumer Research Desk